1 – 3 of 3
      - show: 10
- |
- sort: year (new to old)
        Close
        
            
    
    Embed this list
<iframe src=""
              width=""
              height=""
              allowtransparency="true"
              frameborder="0">
            </iframe>
        - 2016
- 
                        Mark
        Antiretroviral resistance at virological failure in the NEAT 001/ANRS 143 trial: Raltegravir plus darunavir/ritonavir or tenofovir/emtricitabine plus darunavir/ritonavir as first-line ART
    
    - Contribution to journal › Article
 
- 2005
- 
                        Mark
        Antigen-specific beta-chemokine production and CD8(+) T-cell noncytotoxic antiviral activity in HIV-2-infected individuals
    
    - Contribution to journal › Article
 
- 
                        Mark
        Evolution of human immunodeficiency virus type 2 coreceptor usage, autologous neutralization, envelope sequence and glycosylation
    
    - Contribution to journal › Article